Abstract
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic agents, potentially reducing the severity of side effects by preferentially targeting their payload to the tumour site. ADCs are being increasingly used in combination with other agents, including as first-line cancer therapies. As the technology to produce these complex therapeutics has matured, many more ADCs have been approved or are in late-phase clinical trials. The diversification of antigenic targets as well as bioactive payloads is rapidly broadening the scope of tumour indications for ADCs. Moreover, novel vector protein formats as well as warheads targeting the tumour microenvironment are expected to improve the intratumour distribution or activation of ADCs, and consequently their anticancer activity for difficult-to-treat tumour types. However, toxicity remains a key issue in the development of these agents, and better understanding and management of ADC-related toxicities will be essential for further optimization. This Review provides a broad overview of the recent advances and challenges in ADC development for cancer treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
189,00 € per year
only 15,75 € per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
-
Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. Antibody–drug conjugates: the last decade. Pharmaceuticals 13, 245 (2020).
-
Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255–1263 (2022). This article ponders the fact that ADCs have an enlarged therapeutic window in comparison to uncoupled cytotoxins.
-
Kaplon, H., Crescioli, S., Chenoweth, A., Visweswaraiah, J. & Reichert, J. M. Antibodies to watch in 2023. mAbs 15, 2153410 (2023).
-
Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925–932 (2008).
-
Beck, A. et al. Cutting-edge multi-level analytical and structural characterization of antibody–drug conjugates: present and future. Expert. Rev. Proteom. 16, 337–362 (2019).
-
Nabhan, C. et al. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann. Oncol. 15, 1231–1236 (2004).
-
Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508–1516 (2012). This clinical trial showed that fractionation of an ADC dose reduced toxicity without compromising antileukaemic activity.
-
Lambert, J. et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104, 113–119 (2019).
-
Prince, H. M. et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390, 555–566 (2017).
-
Kumar, A. et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J. Clin. Oncol. 39, 2257–2265 (2021).
-
Connors, J. M. et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N. Engl. J. Med. 378, 331–344 (2018).
-
Punnett, A., Tsang, R. W. & Hodgson, D. C. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin. Radiat. Oncol. 20, 30–44 (2010).
-
Moskowitz, C. H. et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132, 2639–2642 (2018).
-
Fornecker, L. M. et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J. Clin. Oncol. 41, 327–335 (2022).
-
Horwitz, S. et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393, 229–240 (2019).
-
Eichenauer, D. A. et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv19–iv29 (2018).
-
Kanate, A. S. et al. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the lymphoma working party of EBMT. JAMA Oncol. 5, 715–722 (2019).
-
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma. NICE https://www.nice.org.uk/guidance/ta577 (2019). This assessment describes how cost-effectiveness is likely to become a key issue in the prescription of ADCs.
-
Stainthorpe, A. et al. Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma: an evidence review group perspective of a NICE single technology appraisal. Pharmacoecon. Open 4, 563–574 (2020).
-
Global sales of ADCs in 2020 — Up to 7 Billion. Biopharma PEG https://www.biochempeg.com/article/329.html (2023).
-
Broccoli, A. et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica 102, 1931–1935 (2017).
-
Pellegrini, C. et al. Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma. Oncotarget 8, 91703–91710 (2017).
-
Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).
-
Sehn, L. H. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 38, 155–165 (2020).
-
Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 22, 790–800 (2021).
-
Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207–221 (2020).
-
Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012). This trial showed the superiority of a single-agent ADC in comparison to standard-of-care combination in patients with advanced breast cancer.
-
Kmietowicz, Z. NICE approves trastuzumab emtansine after deal with drug company. BMJ 357, j2930 (2017).
-
Caparica, R., Brandao, M. & Piccart, M. Systemic treatment of patients with early breast cancer: recent updates and state of the art. Breast 48, S7–S20 (2019).
-
Bahceci, A. et al. Efficacy and safety of trastuzumab emtansine in Her2 positive metastatic breast cancer: real-world experience. Cancer Invest. 39, 473–481 (2021).
-
Cortes, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143–1154 (2022).
-
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9–20 (2022). This trial showed that a HER-2 targeting ADC was highly effective in patients with a low expression of target.
-
Giordano, S. H. et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J. Clin. Oncol. 40, 2612–2635 (2022).
-
Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419–2430 (2020). This trial confirmed the strong antitumour activity of an ADC targeting HER2 in a non-breast tumour type.
-
Banerji, U. et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1124–1135 (2019).
-
Rosenberg, J. E. et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J. Clin. Oncol. 37, 2592–2600 (2019).
-
Cheung, A., Opzoomer, J. & Ilieva, K. M. et al. Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer. Clin. Cancer Res. 24, 5098–5111 (2018).
-
Moore, K. N. et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann. Oncol. 32, 757–765 (2021).
-
Thompson, J. A. et al. Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas. Clin. Cancer Res. 24, 4399–4406 (2018).
-
Schoffski, P., Concin, N. & Suarez, C. et al. A phase 1 study of a CDH6-targeting antibody-drug conjugate in patients with advanced solid tumors with evaluation of inflammatory and neurological adverse events. Oncol. Res. Treat. 44, 547–556 (2021).
-
L’Italien, L. et al. Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies. Clin. Cancer Res. 24, 3465–3474 (2018).
-
Annunziata, C. M. et al. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest. N. Drugs 31, 77–84 (2013).
-
Kim, S. B. et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target. Oncol. 14, 591–601 (2019).
-
Rowinsky, E. K. & Donehower, R. C. Taxol: twenty years later, the story unfolds. J. Natl Cancer Inst. 83, 1778–1781 (1991).
-
Johnson, M. L. et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J. Thorac. Oncol. 16, 1570–1581 (2021).
-
van Berkel, S. S. & van Delft, F. L. Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Drug Discov. Today Technol. 30, 3–10 (2018).
-
Beck, A., Goetsch, L., Dumontet, C. & Corvaia, N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).
-
Lyon, R. Drawing lessons from the clinical development of antibody–drug conjugates. Drug Discov. Today Technol. 30, 105–109 (2018).
-
Herrera, A. F. et al. Anti-CD79B antibody-drug conjugate DCDS0780A in patients with B-cell non-Hodgkin lymphoma: phase 1 dose-escalation study. Clin. Cancer Res. 28, 1294–1301 (2022).
-
Conilh, L., Sadilkova, L., Viricel, W. & Dumontet, C. Payload diversification: a key step in the development of antibody–drug conjugates. J. Hematol. Oncol. 16, 3 (2023).
-
Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790–803 (2010).
-
Serrano-Del Valle, A., Anel, A., Naval, J. & Marzo, I. Immunogenic cell death and immunotherapy of multiple myeloma. Front. Cell Dev. Biol. 7, 50 (2019).
-
Hamblett, K. J. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063–7070 (2004). This article suggested that a high drug-to-antibody ratio was associated with altered pharmacokinetic characteristics compared with those of the corresponding naked antibody, a paradigm which persisted until the development of trastuzumab deruxtecan.
-
Liu, J. et al. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 163, 473–480 (2021).
-
Liu, J. F. et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann. Oncol. 27, 2124–2130 (2016).
-
Pomeroy, A. E., Schmidt, E. V., Sorger, P. K. & Palmer, A. C. Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer 8, 915–929 (2022).
-
Elias, D. J. et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res. 50, 4154–4159 (1990).
-
Figueroa-Vazquez, V. et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol. Cancer Ther. 20, 367–378 (2021).
-
Horwitz, S. et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann. Oncol. 33, 288–298 (2022).
-
Amadori, S. et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J. Clin. Oncol. 34, 972–979 (2016).
-
Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer 125, 2474–2487 (2019).
-
Morgensztern, D. et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin. Cancer Res. 25, 6958–6966 (2019).
-
Janjigian, Y. Y. et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother. Pharm. 65, 833–838 (2010).
-
Puzanov, I. et al. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin. Cancer Res. 17, 3794–3802 (2011).
-
Stein, E. M. et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood 131, 387–396 (2018).
-
Giles, F. J. et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92, 406–413 (2001).
-
McDonald, G. B., Freston, J. W., Boyer, J. L. & DeLeve, L. D. Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (inotuzumab ozogamicin). Hepatology 69, 831–844 (2019).
-
Wahab, A., Rafae, A. & Mushtaq, K. et al. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front. Oncol. 11, 678634 (2021). This article discusses how ocular toxicity has been observed with certain ADCs and may be a limiting factor for widespread use.
-
Farooq, A. V. et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol. Ther. 9, 889–911 (2020).
-
Eaton, J. S., Miller, P. E., Mannis, M. J. & Murphy, C. J. Ocular adverse events associated with antibody–drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31, 589–604 (2015).
-
Abuhelwa, Z., Alloghbi, A., Alqahtani, A. & Nagasaka, M. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs 82, 979–987 (2022). This review discusses pulmonary toxicity observed with certain ADCs and requiring early diagnosis and treatment.
-
Younes, A. et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 14, 1348–1356 (2013).
-
Ansell, S. M. et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N. Engl. J. Med. 387, 310–320 (2022).
-
Zhao, H. et al. A potential mechanism for ADC-induced neutropenia: role of neutrophils in their own demise. Mol. Cancer Ther. 16, 1866–1876 (2017).
-
Zhang, J. et al. Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. Ann. Transl. Med. 9, 1139 (2021).
-
Lee, A., Larck, C. & Moore, D. C. Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. J. Oncol. Pharm. Pract. 28, 49–54 (2022).
-
Mahalingaiah, P. K. et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol. Ther. 200, 110–125 (2019).
-
Wei, C. et al. Where did the linker-payload go? A quantitative investigation on the destination of the released linker-payload from an antibody-drug conjugate with a maleimide linker in plasma. Anal. Chem. 88, 4979–4986 (2016).
-
Gorovits, B. & Krinos-Fiorotti, C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol. Immunother. 62, 217–223 (2013).
-
Aoyama, M., Tada, M., Yokoo, H., Demizu, Y. & Ishii-Watabe, A. FcÎł receptor-dependent internalization and off-target cytotoxicity of antibody–drug conjugate aggregates. Pharm. Res 39, 89–103 (2022).
-
Velasco, R., Domingo-Domenech, E. & Sureda, A. Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy. Cancers 13, 6125 (2021). This article discusses peripheral neutotoxicity as a common adverse event of ADCs containing tubulin binding agent.
-
Perez, E. A. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE. Cancer 125, 3974–3984 (2019).
-
Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 18, 743–754 (2017).
-
Coates, J. T. et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11, 2436–2445 (2021).
-
Loganzo, F. et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody–drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol. Cancer Ther. 14, 952–963 (2015).
-
Yamashita-Kashima, Y. et al. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation. Cancer Chemother. Pharm. 86, 641–654 (2020).
-
Endo, Y. & Wu, W. J. Tumor extrinsic factors mediate primary T-DM1 resistance in HER2-positive breast cancer cells. Cancers 13, 2331 (2021).
-
Skeie, M., Nikolaysen, F., Chitano, Y. & Stang, E. Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: implications for use of T-DM1. J. Cell Mol. Med. 24, 10258–10262 (2020).
-
Zheng, S. et al. Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies. Blood Cancer Discov. 3, 103–115 (2022).
-
Mercogliano, M. F. et al. TNFα-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin. Cancer Res. 23, 636–648 (2017).
-
Jiang, D. et al. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20. Cancer Sci. 112, 3585–3597 (2021).
-
Paul, M. R., Wong, V., Aristizabal, P. & Kuo, D. J. Treatment of recurrent refractory pediatric pre-B acute lymphoblastic leukemia using inotuzumab ozogamicin monotherapy resulting in CD22 antigen expression loss as a mechanism of therapy resistance. J. Pediatr. Hematol. Oncol. 41, e546–e549 (2019).
-
Goyal, A., Patel, S., Goyal, K., Morgan, E. A. & Foreman, R. K. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J. Cutan. Pathol. 46, 823–829 (2019). This article describes how loss of target antigen constitutes a possible mechanism of resistance to ADCs.
-
Chevallier, P. et al. Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving gemtuzumab in the course of the disease. Br. J. Haematol. 143, 744–746 (2008).
-
Rasheed, A. A., Samad, A., Raheem, A., Hirani, S. I. & Shabbir-Moosajee, M. Cd20 expression and effects on outcome of relapsed/ refractory diffuse large B cell lymphoma after treatment with rituximab. Asian Pacif. J. Cancer Prev. 19, 331–335 (2018).
-
Hiraga, J. et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113, 4885–4893 (2009).
-
Kim, S. B. et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer. Int. J. Cancer 139, 2336–2342 (2016).
-
Jacobsen, E. D. et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 125, 1394–1402 (2015).
-
Yurkovetskiy, A. V. et al. Dolaflexin: a novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect. Mol. Cancer Ther. 20, 885–895 (2021).
-
Rahme, R. et al. Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report. Exp. Hematol. 41, 505–507 (2013).
-
Durbin, K. R., Phipps, C. & Liao, X. Mechanistic modeling of antibody-drug conjugate internalization at the cellular level reveals inefficient processing steps. Mol. Cancer Ther. 17, 1341–1351 (2018).
-
Wang, H. et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 108, 1458–1468 (2017).
-
DeVay, R. M. et al. Improved lysosomal trafficking can modulate the potency of antibody drug conjugates. Bioconjug. Chem. 28, 1102–1114 (2017).
-
Hamblett, K. J. et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res. 75, 5329–5340 (2015). This article emphasized for the first time the importance of lysosomal transporters in the cytotoxicity of ADCs.
-
Sauveur, J. et al. Characterization of T-DM1-resistant breast cancer cells. Pharmacol. Res. Perspect. 8, e00617 (2020).
-
Tsui, C. K. et al. CRISPR–Cas9 screens identify regulators of antibody–drug conjugate toxicity. Nat. Chem. Biol. 15, 949–958 (2019).
-
Tang, R. et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 9, 199 (2009).
-
Matsui, H. et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 16, 813–819 (2002).
-
Linenberger, M. L. et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98, 988–994 (2001).
-
Takegawa, N. et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int. J. Cancer 141, 1682–1689 (2017).
-
Godwin, C. D. et al. Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody–drug conjugate therapy of acute leukemia. Leuk. Lymphoma 61, 2990–2994 (2020).
-
Darwich, A. et al. Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1. J. Immunother. Cancer 9, e003224 (2021).
-
Makanga, D. R. et al. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. Oncoimmunology 10, 1936392 (2021).
-
Kamber, R. A. et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597, 549–554 (2021).
-
Bouwstra, R. et al. CD47 expression defines efficacy of rituximab with CHOP in non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma patients (DLBCL), but not in GCB DLBCL. Cancer Immunol. Res. 7, 1663–1671 (2019).
-
Mustafa, N. et al. Determinants of response to daratumumab in Epstein–Barr virus-positive natural killer and T-cell lymphoma. J. Immunother. Cancer 9, e002123 (2021).
-
Allegretti, M. et al. Liquid biopsy identifies actionable dynamic predictors of resistance to trastuzumab emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol. Cancer 20, 151 (2021).
-
Diaz-Gil, L. et al. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. J. Exp. Clin. Cancer Res. 40, 313 (2021).
-
Liang, K., Mei, S., Gao, X., Peng, S. & Zhan, J. Dynamics of endocytosis and degradation of antibody–drug conjugate T-DM1 in HER2 positive cancer cells. Drug Des. Dev. Ther. 15, 5135–5150 (2021).
-
Skidmore, L. et al. ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers. Mol. Cancer Ther. 19, 1833–1843 (2020).
-
Yamazaki, C. M. et al. Antibody–drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat. Commun. 12, 3528 (2021). This article describes how ADCs containing two different payloads may reduce resistance to therapy.
-
Suzuki, M. et al. Visualization of intratumor pharmacokinetics of [fam-]trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis. Clin. Cancer Res. 27, 3970–3979 (2021).
-
Burke, P. J. et al. Glucuronide-linked antibody-tubulysin conjugates display activity in MDR+ and heterogeneous tumor models. Mol. Cancer Ther. 17, 1752–1760 (2018).
-
Conilh, L. et al. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform. Pharmaceuticals 14, 247 (2021).
-
Andreev-Drakhlin, A. Y., Egoryan, G., Shah, A. Y., Msaouel, P., Alhalabi, O. & Gao, J. The evolving treatment landscape of advanced urothelial carcinoma. Curr. Opin. Oncol. 33, 221–230 (2021).
-
Mihalyova, J., Hradska, K., Jelinek, T., Motais, B., Celichowski, P. & Hajek, R. Promising immunotherapeutic modalities for B-cell lymphoproliferative disorders. Int. J. Mol. Sci. 22, 11470 (2021).
-
Bon, G. et al. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER study. J. Exp. Clin. Cancer Res. 39, 279 (2020).
-
Damaschin, C. et al. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. Leukemia 36, 580–582 (2022). This trial demonstrated than an ADC could safely be incorporated in a standard-of-care combination cytotoxic regimen.
-
LaCasce, A. S. et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132, 40–48 (2018).
-
Vinti, L. et al. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Pediatr. Blood Cancer 69, e29557 (2022).
-
Van de Wyngaert, Z. et al. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma. Eur. J. Haematol. 106, 467–472 (2021).
-
Radhakrishnan, V. S. et al. Relapsed refractory Hodgkin lymphoma and brentuximab vedotin-bendamustine combination therapy as a bridge to transplantation: real-world evidence from a middle-income setting and literature review. Front. Oncol. 11, 796270 (2021).
-
Chen, R. et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134, 1144–1153 (2019).
-
Kuruvilla, J. et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 22, 512–524 (2021).
-
Herrera, A. F. et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131, 1183–1194 (2018). The data in this interim analysis show how combination of an ADC with an immune checkpoint inhibitor induced a high response rate in patients with relapsed Hodgkin lymphoma.
-
Cheson, B. D. et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 7, e808–e815 (2020).
-
Massaro, F., Meuleman, N., Bron, D., Vercruyssen, M. & Maerevoet, M. Brentuximab vedotin and pembrolizumab combination in patients with relapsed/refractory Hodgkin lymphoma: a single-centre retrospective analysis. Cancers 14, 982 (2022).
-
Diefenbach, C. S. et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 7, e660–e670 (2020).
-
Zinzani, P. L. et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J. Clin. Oncol. 37, 3081–3089 (2019).
-
Lopez-Miranda, E. et al. Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (Thelma): a single-arm, multicenter, phase Ib trial. Cancers 12, 3509 (2020).
-
Cortes, J. et al. Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. 6, 1203–1209 (2020).
-
Krop, I. E. et al. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 18, 34 (2016).
-
Martin, M. et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Ann. Oncol. 27, 1249–1256 (2016).
-
Kan, S. et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer 15, 726 (2015).
-
Hurvitz, S. A. et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J. Clin. Oncol. 37, 2206–2216 (2019).
-
Masuda, N. et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1 + P), and T-DM1 + P in HER2-positive primary breast cancer. Breast Cancer Res. Treat. 180, 135–146 (2020).
-
Hurvitz, S. A. et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 19, 115–126 (2018). This article described how ADC-containing combinations can be highly active in the neo-adjuvant setting.
-
Patel, T. A. et al. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). Breast Cancer Res. 21, 100 (2019).
-
Jain, S. et al. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res. Treat. 171, 371–381 (2018).
-
Muller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med. 7, 315ra188 (2015).
-
Emens, L. A. et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 21, 1283–1295 (2020).
-
Criscitiello, C., Morganti, S. & Curigliano, G. Antibody–drug conjugates in solid tumors: a look into novel targets. J. Hematol. Oncol. 14, 20 (2021).
-
Sommer, A. et al. Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties. Oncoimmunology 11, 2037216 (2022).
-
Bauzon, M. et al. Maytansine-bearing antibody–drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology 8, e1565859 (2019). This article describes how immunogenic cell death is induced by certain ADCs and may contribute to tumour response.
-
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487–500 (2022).
-
Garg, A. D. et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6, e1386829 (2017).
-
Montes de Oca, R. et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol. Cancer Ther. 20, 1941–1955 (2021).
-
D’Amico, L. et al. A novel anti-HER2 anthracycline-based antibody–drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J. Immunother. Cancer 7, 16 (2019).
-
Khera, E. et al. Cellular-resolution imaging of bystander payload tissue penetration from antibody–drug conjugates. Mol. Cancer Ther. 21, 310–321 (2022).
-
Ashman, N., Bargh, J. D. & Spring, D. R. Non-internalising antibody–drug conjugates. Chem. Soc. Rev. 51, 9182–9202 (2022). This article describes how ADCs binding to non-internalizable targets may induce tumour response.
-
Dal Corso, A., Gebleux, R., Murer, P., Soltermann, A. & Neri, D. A non-internalizing antibody–drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. J. Control Release 264, 211–218 (2017).
-
Giansanti, F. et al. Secreted Gal-3BP is a novel promising target for non-internalizing antibody–drug conjugates. J. Control. Release 294, 176–184 (2019).
-
Fauteux, F. et al. Computational selection of antibody–drug conjugate targets for breast cancer. Oncotarget 7, 2555–2571 (2016).
-
Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br. J. Cancer 117, 1736–1742 (2017).
-
Saha, A., Hyzy, S. & Lamothe, T. et al. A CD45-targeted antibody–drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. Blood 139, 1743–1759 (2022).
-
Westervelt, P. et al. Mgta-117, an anti-CD117 antibody-drug conjugated with amanitin, in participants with relapsed/refractory adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB): safety, pharmacokinetics and pharmacodynamics initial findings from a phase 1/2 study. Blood 140, 2117–2119 (2022). This report descibes how alternative payloads, such as amanitin, have mechanisms of cytotoxicity that are different from those of conventional payloads.
-
Poreba, M. Protease-activated prodrugs: strategies, challenges, and future directions. FEBS J. 287, 1936–1969 (2020).
-
Esfandiari, A., Cassidy, S. & Webster, R. M. Bispecific antibodies in oncology. Nat. Rev. Drug Discov. 21, 411–412 (2022).
-
Pegram, M. D. et al. First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody–drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol. Cancer Ther. 20, 1442–1453 (2021).
-
Zou, D. et al. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada. J. Med. Econ. 25, 324–333 (2022).
-
Podkonjak, T. et al. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. J. Comp. Eff. Res. 11, 193–202 (2022).
-
Sussell, J. et al. Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States. Am. J. Clin. Oncol. 44, 340–349 (2021).
-
Mareque, M. et al. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon. Outcomes Res. 13, 263–277 (2021).
-
Yang, J., Han, J., Zhang, Y., Muhetaer, M., Chen, N. & Yan, X. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Front. Pharm. 13, 924126 (2022).
-
Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).
-
Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood 137, 2890–2901 (2021).
-
Perego, G., Ghidini, A., Luciani, A. & Petrelli, F. Antibody–drug conjugates in treating older patients suffering from cancer: what is the real value? Hum. Vaccin. Immunother. 17, 5575–5578 (2021).
-
Brockelmann, P. J. et al. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem cell transplant: a Germany and United Kingdom retrospective study. Eur. J. Haematol. 99, 553–558 (2017).
-
Silver, A. B., Leonard, E. K., Gould, J. R. & Spangler, J. B. Engineered antibody fusion proteins for targeted disease therapy. Trends Pharmacol. Sci. 42, 1064–1081 (2021).
-
Moolten, F., Zajdel, S. & Cooperband, S. Immunotherapy of experimental animal tumors with antitumor antibodies conjugated to diphtheria toxin or ricin. Ann. NY Acad. Sci. 277, 690–699 (1976).
-
Gilliland, D. G., Steplewski, Z., Collier, R. J., Mitchell, K. F., Chang, T. H. & Koprowski, H. Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc. Natl Acad. Sci. USA 77, 4539–4543 (1980).
-
Akbari, B. et al. Immunotoxins in cancer therapy: review and update. Int. Rev. Immunol. 36, 207–219 (2017).
-
Dinndorf, P., Krailo, M., Liu-Mares, W., Frierdich, S., Sondel, P. & Reaman, G. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J. Immunother. 24, 511–516 (2001).
-
Wu, T. & Zhu, J. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications. Int. Immunopharmacol. 96, 107759 (2021).
-
Kreitman, R. J. et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 32, 1768–1777 (2018).
-
Groth, C. et al. Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transpl. 25, 712–719 (2019). This article shows how ADCs are being explored in non-oncological indications, such as stem cell transplantation.
-
Baur, A. S. et al. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. Blood 122, 2185–2194 (2013).
-
Lutz, M. B., Baur, A. S., Schuler-Thurner, B. & Schuler, G. Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(R) on CD25+ cells. Oncoimmunology 3, e28223 (2014).
-
Murer, P. & Neri, D. Antibody–cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N. Biotechnol. 52, 42–53 (2019).
-
Ding, H. et al. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J. Control. Release 171, 322–329 (2013).
-
Dakhel, S. et al. An attenuated targeted-TNF localizes to tumors in vivo and regains activity at the site of disease. Int. J. Mol. Sci. 22, 10020 (2021).
-
Puca, E. et al. The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer. J. Gastrointest. Oncol. 11, 803–811 (2020).
-
List, T., Casi, G. & Neri, D. A chemically defined trifunctional antibody–cytokine–drug conjugate with potent antitumor activity. Mol. Cancer Ther. 13, 2641–2652 (2014).
-
Kim, S. H. & Jeong, H. J. Soluble expression of a Neo2/15-conjugated single chain Fv against PD-L1 in Escherichia coli. Curr. Issues Mol. Biol. 44, 301–308 (2022).
-
Weiss, T. et al. Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Sci. Transl. Med. 12, eabb2311 (2020). This article shows how immunocytokines aim to elicit local activation of the immune system in tumours.
-
Catania, C. et al. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adh. Migr. 9, 14–21 (2015).
-
Schliemann, C. et al. Phase I study of F16IL2 antibody–cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. Br. J. Haematol. 192, e148–e151 (2021).
-
Rudman, S. M. et al. A phase 1 study of AS1409, a novel antibody–cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin. Cancer Res. 17, 1998–2005 (2011).
-
Carnemolla, B. et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108, 1139–1148 (1989).
-
Kosmehl, H., Berndt, A. & Katenkamp, D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Arch. 429, 311–322 (1996).
-
Peck, M. et al. A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus thiomab antibody-antibiotic conjugate, in healthy volunteers. Antimicrob. Agents Chemother. 63, e02588–18 (2019).
-
Dugal-Tessier, J., Thirumalairajan, S. & Jain, N. Antibody–oligonucleotide conjugates: a twist to antibody–drug conjugates. J. Clin. Med. 10, 838 (2021).
-
Mullard, A. FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment. Nat. Rev. Drug Discov. 21, 548–549 (2022).
-
Lu, H. et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin. Cancer Res. 18, 499–509 (2012).
-
Turaj, A. H., Dahal, L. N., Beers, S. A., Cragg, M. S. & Lim, S. H. TLR-3/9 agonists synergize with anti-ErbB2 mAb-letter. Cancer Res. 77, 3376–3378 (2017).
-
Ackerman, S. E. et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat. Cancer 2, 18–33 (2021).
-
Mullard, A. Targeted protein degraders crowd into the clinic. Nat. Rev. Drug Discov. 20, 247–250 (2021).
-
Schwach, J., Abdellatif, M. & Stengl, A. More than toxins — current prospects in designing the next generation of antibody drug conjugates. Front. Biosci. 27, 240 (2022).
-
Maneiro, M. A. et al. Antibody–PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem. Biol. 15, 1306–1312 (2020). In this article, the authors show how PROTAC technology provides a novel mechanism of action for ADCs.
-
Dragovich, P. S. et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: Exploration of antibody linker, payload loading, and payload molecular properties. J. Med. Chem. 64, 2534–2575 (2021).
-
Dragovich, P. S. Degrader–antibody conjugates. Chem. Soc. Rev. 51, 3886–3897 (2022).
-
Deonarain, M. P. Miniaturised ‘antibody’–drug conjugates for solid tumours? Drug Discov. Today Technol. 30, 47–53 (2018).
-
Richards, D. A. Exploring alternative antibody scaffolds: antibody fragments and antibody mimics for targeted drug delivery. Drug Discov. Today Technol. 30, 35–46 (2018).
-
Zhuang, C., Guan, X., Ma, H., Cong, H., Zhang, W. & Miao, Z. Small molecule–drug conjugates: a novel strategy for cancer-targeted treatment. Eur. J. Med. Chem. 163, 883–895 (2019).
-
Patel, T. K., Adhikari, N., Amin, S. K., Biswas, S., Jah, T. & Ghosh, B. Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery. N. J. Chem. 45, 5291–5321 (2021).
-
Kim, D. H., Seo, J. M., Shin, K. J. & Yang, S. G. Design and clinical developments of aptamer–drug conjugates for targeted cancer therapy. Biomater. Res. 25, 42 (2021).
-
Liu, P., Ga, L., Aodeng, G., Wang, Y. & Ai, J. Aptamer–drug conjugates: new probes for imaging and targeting therapy. Biosens. Bioelectron. 10, 100126 (2022).
-
Adams, G. P. et al. Stability and safety evaluation of ELU001, a targeted C’Dot drug conjugate for the potential treatment of folate receptor α-overexpressing cancers. Cancer Res. 82, 1077–1077 (2022).
-
Leahy, M. F. & Turner, J. H. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117, 45–52 (2011).
-
Lopez-Guillermo, A. et al. A randomized phase II study comparing consolidation with a single dose of (90)Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Leuk. Lymphoma 63, 93–100 (2022).
-
Kolstad, A. et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 4, 4091–4101 (2020).
-
Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
-
Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
-
Darwish, W. M., Bayoumi, N. A., El-Shershaby, H. M. & Moustafa, K. A. A novel gold-polymer–antibody conjugate for targeted (radio-photothermal) treatment of HepG2 cells. J. Biomater. Sci. Polym. Ed. 34, 53–71 (2022).
-
Tafreshi, N. K. et al. Development of targeted alpha particle therapy for solid tumors. Molecules 24, 4314 (2019).
-
Zheng, Y. Z. et al. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma. Sci. Rep. 6, 36447 (2016).
-
Chien, H. P. et al. Expression of ROR1 has prognostic significance in triple negative breast cancer. Virchows Arch. 468, 589–595 (2016).
-
Falay, M. et al. Which markers should the used for diagnostic chronic lymphocytic leukemia immunophenotyping scoring system by flow cytometry? Clin. Lab. 65 https://doi.org/10.7754/Clin.Lab.2019.190316 (2019).
-
Sharkey, R. M. et al. Selective and concentrated accretion of SN-38 with a CEACAM5-targeting antibody-drug conjugate (ADC), labetuzumab govitecan (IMMU-130). Mol. Cancer Ther. 17, 196–203 (2018).
-
Dotan, E. et al. Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody–drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J. Clin. Oncol. 35, 3338–3346 (2017).
-
Waqar, S. N. et al. A phase II study of telisotuzumab vedotin in patients with c-MET-positive stage IV or recurrent squamous cell lung cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin. Lung Cancer 22, 170–177 (2021).
-
Levan, K. et al. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer 17, 303 (2017).
-
Banerjee, S. et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann. Oncol. 29, 917–923 (2018).
Acknowledgements
The authors thank the French National Cancer Institute (INCA) for its support.
Author information
Authors and Affiliations
Contributions
C.D., J.M.R. and A.B. researched data for the article and wrote the article. All authors contributed substantially to discussion of the content and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
C.D. has received research funding from Pierre Fabre and Sanofi, and has worked as a consultant for Sanofi and Bristol-Myers Squibb. He is shareholder and co-founder of Mablink Pharma. J.M.R. is employed by The Antibody Society, a non-profit trade association funded by corporate sponsors that develop antibody therapeutics or provide services to companies that develop antibody therapeutics, and she is Editor-in-Chief of mAbs, a biomedical journal focused on topics relevant to antibody therapeutics development. P.D.S. is an employee of Seattle Genetics. J.M.L. was an employee of ImmunoGen, Inc. from 1987 to 2017, Waltham, MA, USA. ImmunoGen developed the maytansinoid linker-payload technology utilized in the ADCs trastuzumab emtansine and mirvetuximab soravtansine discussed in this paper. Since 2018, J.M.L. has consulted for ImmunoGen and several other biotechnology companies developing ADCs. A.B. is an employee of the Pierre Fabre Research Institute, Saint-Julien en Genevois, France, which has licensed telisotuzumab (ABT-700) anti-cMet antibody to AbbVie and developed the ADC telisotuzumab vedotin.
Peer review
Peer review information
Nature Reviews Drug Discovery thanks Paul Carter and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
National Comprehensive Cancer Network: www.nccn.org
Supplementary information
Glossary
- Bystander effect
-
A biological effect in which a payload released from a dying tumour cell that has internalized an antibody–drug conjugate will destroy neighbouring cells independently of their target antigen expression.
- C’Dot–drug conjugates
-
Nanoparticle–drug conjugates of very small size in comparison to antibodies.
- Drug-to-antibody ratios (DARs)
-
The average number of drug molecules that are conjugated to an antibody in an antibody–drug conjugate.
- Linker
-
The chemical connector between the antibody and payload; it may be non-cleavable, cleavable or self-immolative; cleavage can take place with proteases, hydrolysis or reduction mechanisms.
- Payload
-
A small-molecule cytotoxic chemotherapeutic (also known as a warhead).
- Probodies
-
Proteolytically activated antibodies engineered to remain inert until activated locally in target tissue.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dumontet, C., Reichert, J.M., Senter, P.D. et al. Antibody–drug conjugates come of age in oncology. Nat Rev Drug Discov (2023). https://ift.tt/RmIh65d
-
Accepted:
-
Published:
-
DOI: https://ift.tt/RmIh65d
"come" - Google News
June 12, 2023 at 09:45PM
https://ift.tt/Wkz9P58
Antibody–drug conjugates come of age in oncology - Nature.com
"come" - Google News
https://ift.tt/rz4UOoK
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Antibodydrug conjugates come of age in oncology - Nature.com"
Post a Comment